Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Design Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DSGN
Nasdaq
8731
https://www.designtx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Design Therapeutics Inc
Independent Director of Design Therapeutics Picks Up 88% More Stock
- Mar 27th, 2024 10:15 am
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
- Mar 23rd, 2024 12:23 pm
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
- Mar 20th, 2024 2:31 pm
Q4 2023 Design Therapeutics Inc Earnings Call
- Mar 20th, 2024 10:58 am
Design Therapeutics Outlines Progress Across GeneTACâ„¢ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mar 19th, 2024 8:01 pm
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
- Mar 12th, 2024 10:30 am
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
- Dec 18th, 2023 5:00 pm
Positive Signs As Multiple Insiders Buy Design Therapeutics Stock
- Nov 25th, 2023 12:35 pm
Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update
- Nov 15th, 2023 12:28 am
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
- Nov 13th, 2023 9:05 pm
Why Shares of Design Therapeutics Are Plummeting on Tuesday
- Aug 15th, 2023 7:02 pm
Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls
- Aug 15th, 2023 1:59 pm
4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi
- Aug 15th, 2023 6:34 am
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
- Aug 14th, 2023 8:05 pm
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
- Aug 14th, 2023 8:01 pm
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \
- Jun 18th, 2023 12:03 pm
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
- May 31st, 2023 10:30 am
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
- May 9th, 2023 8:05 pm
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
- May 8th, 2023 10:05 am
Design Therapeutics to Present Preclinical Data on its GeneTACâ„¢ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
- Apr 24th, 2023 10:30 am
Scroll